What's new

Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance

Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance

Feb 12, 2025 - 15:58
 0
Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance
Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 mg, product-specific bioequivalence guidance
Read More

Tags:

Previous Article

STAT+: Is Trump’s new order a reprieve for biotech?

Next Article

Slideshow: Valentine’s Day introductions to fall in love with

Related Posts

EMA concludes review of weight management medicine Mysimba

EMA concludes review of weight management medicine Mysimba

Mar 28, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Blood and lymphatic system disorders, PIP number: P/0040/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 24, 2025  0

Human medicines European public assessment report (EPAR): Prevymis, letermovir, Date of authorisation: 08/01/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 16, 2025  0